Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-22-012990
Filing Date
2022-03-31
Accepted
2022-03-31 20:15:26
Documents
1
Period of Report
2022-03-29

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 22765
  Complete submission text file 0000899243-22-012990.txt   24993
Mailing Address C/O ADJUVANT CAPITAL, L.P. 501 FIFTH AVENUE, SUITE 1404 NEW YORK NY 10017
Business Address C/O ADJUVANT CAPITAL, L.P. 501 FIFTH AVENUE, SUITE 1404 NEW YORK NY 10017 917-334-0724
Adjuvant Global Health Technology Fund, L.P. (Reporting) CIK: 0001783165 (see all company filings)

State of Incorp.: E9
Type: 4 | Act: 34 | File No.: 001-41331 | Film No.: 22795200

Mailing Address C/O ADJUVANT CAPITAL, L.P. 501 FIFTH AVENUE, SUITE 1404 NEW YORK NY 10017
Business Address C/O ADJUVANT CAPITAL, L.P. 501 FIFTH AVENUE, SUITE 1404 NEW YORK NY 10017 917-334-0724
Adjuvant Global Health Technology Fund DE, L.P. (Reporting) CIK: 0001799812 (see all company filings)

State of Incorp.: DE
Type: 4 | Act: 34 | File No.: 001-41331 | Film No.: 22795199

Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Issuer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations